<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093626</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02624</org_study_id>
    <secondary_id>NCI-2012-02624</secondary_id>
    <secondary_id>CDR0000389246</secondary_id>
    <secondary_id>GOG-0170F</secondary_id>
    <secondary_id>GOG-0170F</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00093626</nct_id>
  </id_info>
  <brief_title>Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer</brief_title>
  <official_title>A Phase II Evaluation of BAY 43-9006 (Sorafenib, Nexavar®, NCI-Supplied Agent, NSC #724772) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by&#xD;
      blocking the enzymes necessary for their growth. This phase II trial is studying how well&#xD;
      sorafenib works in treating patients with persistent or recurrent ovarian epithelial or&#xD;
      peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the efficacy of sorafenib in patients with persistent or recurrent ovarian&#xD;
      epithelial or primary peritoneal carcinoma.&#xD;
&#xD;
      II. Determine 6-month progression-free survival of patients treated with this drug.&#xD;
&#xD;
      III. Determine the toxicity of this drug, in terms of frequency and severity of adverse&#xD;
      events encountered, in these patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the clinical response rate (partial and complete response) in patients treated&#xD;
      with this drug.&#xD;
&#xD;
      II. Determine the duration of progression-free and overall survival of patients treated with&#xD;
      this drug.&#xD;
&#xD;
      III. Correlate prognostic variables (platinum sensitivity, performance status, and histology&#xD;
      [clear cell and mucinous type]) with response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years and then every 6 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 22-60 patients will be accrued for this study within 6-13&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of adverse events as assessed by CTCAE v3.0</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 months</time_frame>
    <description>Will be evaluated using proportional hazards modeling and Fisher's exact test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be evaluated using proportional hazards modeling and Fisher's exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of progression-free survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be evaluated using proportional hazards modeling and Fisher's exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of clinical response (complete and partial response) defined by RECIST criteria</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic variables (platinum sensitivity, performance status, and cellular histology [clear cell or mucinous type])</measure>
    <time_frame>Up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Primary Peritoneal Carcinoma</condition>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib Tosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
    <other_name>BAY 43-9006 Tosylate</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>sorafenib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial or primary peritoneal carcinoma&#xD;
&#xD;
               -  Persistent or recurrent disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Measurable disease is defined as at least 1 unidimensionally measurable lesion ≥&#xD;
                  20 mm by conventional techniques (including palpation, plain x-ray, CT scan, or&#xD;
                  MRI) OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Evaluable disease is defined as at least 1 of the following:&#xD;
&#xD;
                    -  CA 125 ≥ 2 times upper limit of normal (ULN)&#xD;
&#xD;
                    -  Ascites and/or pleural effusion attributed to tumor&#xD;
&#xD;
                    -  Solid and/or cystic abnormalities on radiographic imaging that do not meet&#xD;
                       RECIST definition for target lesions&#xD;
&#xD;
          -  Must have received 1 prior platinum-based chemotherapeutic regimen for primary&#xD;
             disease, including carboplatin, cisplatin, or another organoplatinum compound&#xD;
&#xD;
               -  Initial treatment may have included high-dose therapy, consolidation, or extended&#xD;
                  therapy administered after surgical or non-surgical assessment&#xD;
&#xD;
               -  Platinum-resistant according to 1 of the following criteria:&#xD;
&#xD;
                    -  Treatment-free interval of &lt; 12 months after platinum therapy&#xD;
&#xD;
                    -  Disease progression during platinum-based therapy&#xD;
&#xD;
                    -  Persistent disease after a platinum-based regimen&#xD;
&#xD;
          -  Ineligible for higher priority GOG protocol (e.g., any active phase III GOG protocol&#xD;
             for the same patient population)&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
          -  Performance status - GOG 0-2 (for patients who received 1 prior treatment regimen)&#xD;
&#xD;
          -  Performance status - GOG 0-1 (for patients who received 2 prior treatment regimens)&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  No known bleeding diathesis&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  SGOT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  Able to take oral medication&#xD;
&#xD;
          -  No bowel obstruction or persistent vomiting&#xD;
&#xD;
          -  No requirement for parenteral feedings&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 3 months&#xD;
             after study participation&#xD;
&#xD;
          -  No sensory or motor neuropathy &gt; grade 1&#xD;
&#xD;
          -  No active or ongoing infection requiring antibiotics&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biological composition to sorafenib&#xD;
&#xD;
          -  No serious chronic skin conditions (i.e., psoriasis or dermatitis) that would preclude&#xD;
             study participation&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  At least 3 weeks since prior immunologic agents for the malignancy&#xD;
&#xD;
          -  More than 4 weeks since prior mouse antibodies (for patients with evaluable disease&#xD;
             only)&#xD;
&#xD;
          -  No concurrent prophylactic growth factors (e.g., filgrastim [G-CSF])&#xD;
&#xD;
          -  No concurrent prophylactic thrombopoietic agents except in the case of recurrent grade&#xD;
             4 thrombocytopenia&#xD;
&#xD;
          -  No other concurrent biological agents for the primary tumor&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No prior non-cytotoxic chemotherapy for persistent or recurrent disease&#xD;
&#xD;
          -  No concurrent chemotherapy for the primary tumor&#xD;
&#xD;
          -  At least 1 week since prior hormonal therapy for the malignancy&#xD;
&#xD;
          -  No concurrent hormonal therapy for the primary tumor&#xD;
&#xD;
               -  Concurrent hormone replacement therapy allowed&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 25% of marrow-bearing areas&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior surgery involving the peritoneum or pleura (for patients&#xD;
             with evaluable disease only)&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  At least 3 weeks since other prior therapy for the malignancy&#xD;
&#xD;
          -  No more than 1 additional prior cytotoxic regimen for persistent or recurrent disease&#xD;
&#xD;
          -  No prior sorafenib&#xD;
&#xD;
          -  No prior anticancer treatment that would preclude study participation&#xD;
&#xD;
          -  No concurrent therapeutic oral anticoagulation therapy (i.e., warfarin)&#xD;
&#xD;
               -  Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for central&#xD;
                  venous access devices allowed provided INR is &lt; 1.5&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational or commercial agents or therapies for the&#xD;
             malignancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Matei</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Japan</country>
  </removed_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 6, 2004</study_first_submitted>
  <study_first_submitted_qc>October 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2004</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

